iifl-logo

Sequent Scientific Ltd Half Yearly Results

189.3
(0.77%)
Jun 9, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Mar-2025Sept-2024Mar-2024Sept-2023Mar-2023

Gross Sales

792.51

758.86

690.56

679.18

741.98

Excise Duty

0

0

0

0

0

Net Sales

792.51

758.86

690.56

679.18

741.98

Other Operating Income

0

0

0

0

0

Other Income

7.5

7.19

8.52

2.44

4.6

Total Income

800.01

766.05

699.07

681.62

746.58

Total Expenditure

712.42

682.13

637.99

687.72

796.61

PBIDT

87.59

83.92

61.09

-6.11

-50.03

Interest

30.08

30.67

25.03

23.06

20.6

PBDT

57.51

53.25

36.06

-29.17

-70.62

Depreciation

33.1

33.35

31.94

29.6

28.38

Minority Interest Before NP

0

0

0

0

0

Tax

21.76

19.13

7.98

5.97

3.73

Deferred Tax

-14.21

-14.63

-15.8

-23.18

-0.52

Reported Profit After Tax

16.86

15.4

11.94

-41.56

-102.22

Minority Interest After NP

4.1

6.28

4.6

1.66

0.23

Net Profit after Minority Interest

12.76

9.12

7.35

-43.23

-102.44

Extra-ordinary Items

-0.65

-0.17

-1.95

-13.88

-61.6

Adjusted Profit After Extra-ordinary item

13.41

9.29

9.3

-29.35

-40.84

EPS (Unit Curr.)

0.51

0.37

0.29

-1.74

0

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

0

0

Equity

50.06

49.92

49.89

49.89

49.89

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

11.05

11.05

8.84

-0.89

-6.74

PBDTM(%)

-

-

-

-

-

PATM(%)

2.12

2.02

1.72

-6.11

-13.77

Sequent Scien.: Related NEWS

Sequent Scientific jumps ~12% on ₹8,000 Crore merger with Viyash Life
27 Sep 2024|03:01 PM

Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.